Scope FluidicsS.A.
Other research and experimental development on natural sciences and engineering
Overview
Scope Fluidics is a biotechnology company that designs and develops microfluidic technologies for medical diagnostics and healthcare. It has created the PCR|ONE system for the rapid diagnosis of diseases caused by bacterial and viral agents and the BacterOMIC system for assessing the drug susceptibility of microorganisms. The company operates through special-purpose vehicles to address critical needs in medical diagnostics.
Financials
Revenue history (in k)
Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.
Stock quotes
- Open
- PLN 132.00
- High
- PLN 133.00
- Low
- PLN 131.00
- Volume
- 562
- Avg. vol.
- 1.83K
- Market cap
- PLN 420.75M
- P/E ratio
- –
- EPS
- -PLN 15.91
- Shares outstanding
- 3.17M
- 52-week
- PLN 117.20 – 136.00
- Dividend yield
- 64.44%
- Dividend
- PLN 85.57
- Ex dividend date
- Mar 24, 2023
- ISIN
- PLSCPFL00018
- Exchange
- GPW Main Market
Quarterly results
| Period | Revenue | EBIT | Net profit |
|---|---|---|---|
| Q2 2026 | USD 8.64k | USD -3.17m | USD -2.74m |
| Q1 2026 | USD 7.29k | USD -3.92m | USD -3.64m |
| Q4 2025 | USD -150.18k | USD -4.09m | USD -3.88m |
| Q3 2025 | USD 5.52k | USD -3.12m | USD -2.85m |
Results for Q3 2026:Nov 30, 2026
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2025.
Results vs industry
News
Scope Fluidics Secures Another U.S. Patent for the BACTEROMIC System
Scope Fluidics signs agreement for distribution of the BACTEROMIC system in 10 European markets
Scope Fluidics Signs Agreement for Clinical Trials of the BACTEROMIC System PBC Panel
Scope Fluidics Signs Agreement for Clinical Trials of the BACTEROMIC System PBC Panel
Scope Fluidics Secures New Location for Semi-Automated BACTEROMIC Panel Production Line
Scope Fluidics Secures New Location for Semi-Automated BACTEROMIC Panel Production Line
BACTEROMIC system with UNI FAST Panel receives CE IVDR certification
BACTEROMIC system with UNI FAST Panel receives CE IVDR certification
BACTEROMIC System with UNI FAST Panel Receives CE IVDR Certification
BACTEROMIC System with UNI FAST Panel Receives CE IVDR Certification
Industry
Bank accounts
Registered as a VAT taxpayer on 2011-01-31. Active
08 2490 0005 0000 4600 8015 8075- 11 2490 0005 0000 4600 1874 5090
12 1090 1056 0000 0001 5197 5646
Debt
No entries in the National Debtors Register (KRZ). No proceedings in KRZ
Public aid
4 public aid cases recorded, with a total value of $22,557.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Sep 20, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | $4,184$4,184 | Prezes Zakładu Ubezpieczeń Społecznych | |
| May 30, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | $4,472$4,472 | Prezes Zakładu Ubezpieczeń Społecznych | |
| May 30, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | $3,644$3,644 | Prezes Zakładu Ubezpieczeń Społecznych |
Tenders
No recorded participation in tenders.
Trademarks
Scope Fluidics holds 2 active trademarks registered with the Polish Patent Office. The first mark was filed in 2012.
| Mark | Protected until | |
|---|---|---|
| Scope Fluidics(word) | Oct 19, 2033 | |
| SCOPE fluidics | Jul 10, 2032 |
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
 BDO | BDO register entry | Active |
Authorized Representatives
Manner of representation
The company is represented by two members of the management board acting jointly, or one member of the management board together with a commercial proxy.
Supervisory board
Beneficial owners
No beneficial owners recorded for the company Scope Fluidics.
Subsidiaries
| Name | Share value | Stake | ||
|---|---|---|---|---|
Bacteromicsp. z o.o. | 10,022,960.56 USD | 100% |
Capital group
| Name | Ownership |
|---|---|
| 71% |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| GenomedS.A. | $7,373,750.46 | genomed.pl | ||
| Sidlysp. z o.o. | $4,977,649.42 | sidly.eu | ||
| BiotechnaS.A. | $2,472,888.07 | bsbiotechna.com | ||
| IntodnaS.A. | $2,286,118.76 | intodna.com | ||
| Read-GeneS.A. | $2,163,474.84 | read-gene.com | ||
| RDLSsp. z o.o. | $1,680,515.32 | rdls.pl | ||
| Eurxsp. z o.o. | $1,644,555.44 | eurx.com.pl | ||
| FamicordtxS.A. | $1,365,068.41 | famicordtx.com | ||
| COS LabP.S.A. | $1,028,123.83 | coslab.pl | ||
| MTCS.A. | $825,216.26 | mtcenter.pl |
Change history
| Date | Event | |
|---|---|---|
| 2025-11-26 | Share capital change (272,593.00 PLN → 316,827.10 PLN) | |
| 2023-01-26 | Address change (Ul. Duchnicka 3, Bud.16/Wejście A, 01-796, Warszawa → Ul. Ogrodowa 58, 00-876, Warszawa) | |
| 2022-11-15 | Share capital change (268,620.50 PLN → 272,593.00 PLN) | |
| 2020-11-30 | Share capital change (255,829.00 PLN → 268,620.50 PLN) | |
| 2020-04-07 | Share capital change (254,694.00 PLN → 255,829.00 PLN) |
FAQ
Last updated: 2026-07-16